168 related articles for article (PubMed ID: 33110096)
1. Structural modeling of GSK3β implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs.
Balasubramaniam M; Mainali N; Bowroju SK; Atluri P; Penthala NR; Ayyadevera S; Crooks PA; Shmookler Reis RJ
Sci Rep; 2020 Oct; 10(1):18326. PubMed ID: 33110096
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid-mediated activation of GSK3β promotes tau phosphorylation and impairs memory in type 2 diabetes.
Dey A; Hao S; Wosiski-Kuhn M; Stranahan AM
Neurobiol Aging; 2017 Sep; 57():75-83. PubMed ID: 28609678
[TBL] [Abstract][Full Text] [Related]
3. The GSK3β inhibitor, TDZD-8, rescues cognition in a zebrafish model of okadaic acid-induced Alzheimer's disease.
Koehler D; Shah ZA; Williams FE
Neurochem Int; 2019 Jan; 122():31-37. PubMed ID: 30392874
[TBL] [Abstract][Full Text] [Related]
4. Activation of AKT/GSK3β pathway by TDZD-8 attenuates kainic acid induced neurodegeneration but not seizures in mice.
Bhowmik M; Khanam R; Saini N; Vohora D
Neurotoxicology; 2015 Jan; 46():44-52. PubMed ID: 25453207
[TBL] [Abstract][Full Text] [Related]
5. Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend
Kakraba S; Ayyadevara S; Mainali N; Balasubramaniam M; Bowroju S; Penthala NR; Atluri R; Barger SW; Griffin ST; Crooks PA; Shmookler Reis RJ
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895969
[TBL] [Abstract][Full Text] [Related]
6. Xanthone glucoside 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3β and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk.
Mangangcha IR; Brojen Singh RK; Lebeche D; Ali S
J Biomol Struct Dyn; 2022 Oct; 40(17):7868-7884. PubMed ID: 33769184
[TBL] [Abstract][Full Text] [Related]
7. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
Zhu J; Wu Y; Xu L; Jin J
Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
[TBL] [Abstract][Full Text] [Related]
8. Binding and stability of indirubin-3-monoxime in the GSK3β enzyme: a molecular dynamics simulation and binding free energy study.
Saravanan K; Hunday G; Kumaradhas P
J Biomol Struct Dyn; 2020 Mar; 38(4):957-974. PubMed ID: 30963817
[TBL] [Abstract][Full Text] [Related]
9. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
Pardhi T; Vasu K
J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel small molecules against GSK3β for Alzheimer's disease using chemoinformatics approach.
Shukla R; Munjal NS; Singh TR
J Mol Graph Model; 2019 Sep; 91():91-104. PubMed ID: 31202091
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological targeting of GSK3β confers protection against podocytopathy and proteinuria by desensitizing mitochondrial permeability transition.
Wang Z; Bao H; Ge Y; Zhuang S; Peng A; Gong R
Br J Pharmacol; 2015 Feb; 172(3):895-909. PubMed ID: 25262943
[TBL] [Abstract][Full Text] [Related]
12. In silico screening and identification of potential GSK3β inhibitors.
Daggupati T; Pamanji R; Yeguvapalli S
J Recept Signal Transduct Res; 2018 Aug; 38(4):279-289. PubMed ID: 29947280
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of glycogen synthase kinase-3β prevents NSAID-induced acute kidney injury.
Bao H; Ge Y; Zhuang S; Dworkin LD; Liu Z; Gong R
Kidney Int; 2012 Apr; 81(7):662-73. PubMed ID: 22258319
[TBL] [Abstract][Full Text] [Related]
14. Microsecond molecular dynamics simulations and dynamic network analysis provide understanding of the allosteric inactivation of GSK3β induced by the L343R mutation.
Li J; Fu Q; Liang Y; Cheng B; Li X
J Mol Model; 2019 Apr; 25(5):111. PubMed ID: 30949773
[TBL] [Abstract][Full Text] [Related]
15. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
16. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
Martinez A; Alonso M; Castro A; Pérez C; Moreno FJ
J Med Chem; 2002 Mar; 45(6):1292-9. PubMed ID: 11881998
[TBL] [Abstract][Full Text] [Related]
17. Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives.
Castro A; Encinas A; Gil C; Bräse S; Porcal W; Pérez C; Moreno FJ; Martínez A
Bioorg Med Chem; 2008 Jan; 16(1):495-510. PubMed ID: 17919914
[TBL] [Abstract][Full Text] [Related]
18. The binding and phosphorylation of Thr231 is critical for Tau's hyperphosphorylation and functional regulation by glycogen synthase kinase 3beta.
Lin YT; Cheng JT; Liang LC; Ko CY; Lo YK; Lu PJ
J Neurochem; 2007 Oct; 103(2):802-13. PubMed ID: 17680984
[TBL] [Abstract][Full Text] [Related]
19. How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M
J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861
[TBL] [Abstract][Full Text] [Related]
20. GSK-3β inhibitor TDZD-8 reduces neonatal hypoxic-ischemic brain injury in mice.
Huang S; Wang H; Turlova E; Abussaud A; Ji X; Britto LR; Miller SP; Martinez A; Sun HS; Feng ZP
CNS Neurosci Ther; 2017 May; 23(5):405-415. PubMed ID: 28256059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
